Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Microglial-mediated clearance of aggregated tau refers to the process by which microglia recognize, internalize, and degrade pathological forms of tau protein. Microglia can internalize both monomeric and fibrillar forms of extracellular tau through phagocytosis. The efficiency with which microglia clear tau aggregates depends on several factors, including the phosphorylation state of tau, receptor interactions (CX3CR1, TLRs), and lysosomal function. In AD, microglia play a dual role: protective by engulfing and degrading extracellular aggregated tau, and pathogenic by releasing exosomes containing seeding-competent tau species. Genetic variants affecting microglial function—such as those in TREM2—are associated with altered risk for AD. Experimental manipulation enhancing microglial phagocytic activity has been shown to reduce amyloid plaque load; similar strategies are being explored for promoting clearance of pathological tau species.
Enhancing microglial phagocytic activity to promote clearance of pathological tau species
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Microglial-mediated clearance of aggregated tau.